🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against superbug strains of the bacteria, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the management of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to data published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This establishes an comparable level with the current standard treatment, which involves a dual-drug approach. The trial involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.

Medical professionals directly involved have shared positive views. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for public health efforts. This is deemed crucial to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.